PMID- 29196150
OWN - NLM
STAT- MEDLINE
DCOM- 20180504
LR  - 20181202
IS  - 1872-8227 (Electronic)
IS  - 0168-8227 (Linking)
VI  - 136
DP  - 2018 Feb
TI  - SGLT2 inhibitors with cardiovascular benefits: Transforming clinical care in Type 
      2 diabetes mellitus.
PG  - 23-31
LID - S0168-8227(17)31098-7 [pii]
LID - 10.1016/j.diabres.2017.11.023 [doi]
AB  - Cardiovascular risk reduction in individuals with Type 2 diabetes mellitus (T2DM) 
      is a key part of clinical management. Sodium-glucose co-transporter (SGLT2) 
      inhibitors improve glycaemic control, reduce body weight and decrease blood 
      pressure. In addition, the SGLT2 inhibitors empagliflozin and canagliflozin 
      reduced the risk of composite cardiovascular events in high-risk individuals with 
      T2DM in the EMPA-REG OUTCOME trial and the CANVAS Program, respectively. 
      Empagliflozin also reduced cardiovascular deaths and improved renal outcomes. 
      This class of agents should be considered in people with established 
      cardiovascular disease, usually in combination with other glucose lowering 
      medications, when satisfactory glycaemic control has not been achieved. The dose 
      of insulin or sulfonylureas may need to be lowered when used with SGLT2 
      inhibitors, to reduce the risk of hypoglycaemia. Genitourinary infections can 
      occur with SGLT2 inhibitors in a small proportion of people. In people with 
      osteoporosis or prior amputation, it may be prudent to use empagliflozin rather 
      than canagliflozin, based on the increased risk for bone fractures and 
      amputations observed with canagliflozin in the CANVAS Program. SGLT2 inhibitors 
      have the potential to transform the clinical care of persons with T2DM by not 
      only improving glycaemic control but also reducing blood pressure, body weight 
      and diabetes-related end-organ complications.
CI  - Copyright (c) 2017 Elsevier B.V. All rights reserved.
FAU - d'Emden, Michael
AU  - d'Emden M
AD  - Royal Brisbane and Women's Hospital, Brisbane, QLD, Australia.
FAU - Amerena, John
AU  - Amerena J
AD  - Geelong Hospital, Geelong, VIC, Australia.
FAU - Deed, Gary
AU  - Deed G
AD  - Mediwell Medical Clinic, Coorparoo, QLD, Australia.
FAU - Pollock, Carol
AU  - Pollock C
AD  - Kolling Institute, Royal North Shore Hospital, University of Sydney, Sydney, NSW, 
      Australia.
FAU - Cooper, Mark E
AU  - Cooper ME
AD  - Department of Diabetes, Central Clinical School, Monash University, Melbourne, 
      VIC, Australia. Electronic address: mark.cooper@monash.edu.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20171202
PL  - Ireland
TA  - Diabetes Res Clin Pract
JT  - Diabetes research and clinical practice
JID - 8508335
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Sodium-Glucose Transporter 2 Inhibitors)
SB  - IM
MH  - Cardiovascular Diseases/*drug therapy
MH  - Diabetes Mellitus, Type 2/blood/*drug therapy/pathology
MH  - Humans
MH  - Hypoglycemic Agents/pharmacology/*therapeutic use
MH  - Risk Factors
MH  - *Sodium-Glucose Transporter 2 Inhibitors
OTO - NOTNLM
OT  - Cardiovascular risk reduction
OT  - Empagliflozin
OT  - Glycaemic control
OT  - Improved renal outcomes
OT  - Type 2 diabetes mellitus
EDAT- 2017/12/03 06:00
MHDA- 2018/05/05 06:00
CRDT- 2017/12/03 06:00
PHST- 2017/07/13 00:00 [received]
PHST- 2017/11/07 00:00 [revised]
PHST- 2017/11/20 00:00 [accepted]
PHST- 2017/12/03 06:00 [pubmed]
PHST- 2018/05/05 06:00 [medline]
PHST- 2017/12/03 06:00 [entrez]
AID - S0168-8227(17)31098-7 [pii]
AID - 10.1016/j.diabres.2017.11.023 [doi]
PST - ppublish
SO  - Diabetes Res Clin Pract. 2018 Feb;136:23-31. doi: 10.1016/j.diabres.2017.11.023. 
      Epub 2017 Dec 2.